Drug Delivery Systems, 2006
Introduction

Drug delivery has changed. We are now looking at ways of enhancing CNS delivery through nasal administration, the role nanotechnology can play in targeted drug delivery and more novel delivery systems, such as PEGylation platforms. These technological advances allow increased delivery to target sites, maximise drug absorption and extend drug action. By considering the commercial effects of new emerging technology now, you will increase viability of your products, business relationships and investments for the future. To do this you will no doubt have to answer questions such as, do I chose new technology or a proven approach? Should I reposition as a specialty pharma? At what stage do I apply drug delivery to development projects?

This 3-day event being held 7-9 November 2006, will highlight the successful real-life strategies for improving business development, increasing value from collaborative partnerships and achieving commercialisation in today’s market. Now in its third year visiongain’s Drug Delivery Systems conference will enable you with an understanding of novel delivery systems, emerging drug delivery technologies and different partnership models, preparing you for 2007 and beyond. Whether you are a solution provider, prospective partner or an investor, the 3rd Annual Drug Delivery Systems conference will address the topics you care about, and provide you with the answers you need to speed your decision making process.

By attending this conference you will:

Examine ways to de-risk when delivery technology is applied in early development
Analyse how to smoothly transfer from research to development by pre-formulation and analytical support
Consider how to find the appropriate device development partner
Gain an understanding of how to effectively apply emerging technologies to your products
Evaluate how to prepare to evolve from a drug delivery to a specialty pharma company and forming new partnerships with big pharma
Explore practical methods for pre-clinical assessment of the efficacy, toxicity and mechanism of action of selected polymers
POST-CONFERENCE INTERACTIVE WORKSHOP
Best practise in drug delivery partnerships - 07 November 2006
Led by: Steve Poile, Director Licensing & Alliances and Co-Founder, Bridgehead International Ltd.
Robert Fishleigh, Director Strategy & Planning, Bridgehead International Ltd.

AND FOR SOME BACKGROUND READING....

Whether you wish to attend the conference or not we are also pleased to announce the availability of the following features:

Product Lifecycle Management, 2006
Inhalable Drug Delivery
Biogenerics: Challenges and Promise
Maximizing Product Returns Through Reformulation
Drug Delivery in Central Nervous System Diseases
Drug Delivery in Cancer
Transdermal Drug Delivery
Injectable Drug Delivery: Probing the Route to Growth
Advanced Drug Delivery

Drug Delivery in Central Nervous System Diseases - technologies, markets and companies

Summary

The delivery of drugs to central nervous system (CNS) is a challenge in the treatment of neurological disorders. Drugs may be administered directly into the CNS or administered systematically (e.g., by intravenous injection) for targeted action in the CNS. The major challenge to CNS drug delivery is the blood-brain barrier (BBB), which limits the access of drugs to the brain substance.

This report:

Introduces the basics of drug delivery to the CNS

Describes the blood-brain barrier

Discusses methods of drug delivery to the CNS

Evaluates delivery of cell, gene and antisense therapies to the CNS

Analyses drug delivery in the treatment of CNS disorders

Quantifies markets for drug delivery in CNS disorders

Provides information on companies involved in the field
Advances in understanding of the cell biology of the BBB have opened new avenues and possibilities for improved drug delivery to the CNS. Several carrier or transport systems, enzymes, and receptors that control the penetration of molecules have been identified in the BBB endothelium. Receptor-mediated transcytosis can transport peptides and proteins across the BBB. Methods are available to assess the BBB permeability of drugs at the discovery stage to avoid development of drugs that fail to reach their target site of action in the CNS.

Various strategies that have been used for manipulating the blood-brain barrier for drug delivery to the brain include osmotic and chemical opening of the blood-brain barrier as well as the use of transport/carrier systems. Other strategies for drug delivery to the brain involve bypassing the BBB. Various pharmacological agents have been used to open the BBB and direct invasive methods can introduce therapeutic agents into the brain substance. It is important to consider not only the net delivery of the agent to the CNS, but also the ability of the agent to access the relevant target site within the CNS. Various routes of administration as well as conjugations of drugs, e.g., with liposomes and nanoparticles, are considered. Some routes of direct administration to the brain are non-invasive such as transnasal route whereas others involve entry into the CNS by devices and needles such as in case of intrathecal and intracerebroventricular delivery. Systemic therapy by oral and parenteral routes is considered along with sustained and controlled release to optimize the CNS action of drugs. Among the three main approaches to drug delivery to the CNS - systemic administration, injection into CSF pathways, and direct injection into the brain - the greatest developments is anticipated to occur in the area of targeted delivery by systemic administration.

Many of the new developments in the treatment of neurological disorders will be biological therapies and these will require innovative methods for delivery. Cell, gene and antisense therapies are not only innovative treatments for CNS disorders but also involve sophisticated delivery methods. RNA interference (RNAi) as a form of antisense therapy is also described.

The role of drug delivery is depicted in the background of various therapies for neurological diseases including drugs in development and the role of special delivery preparations. Pain is included as it is considered to be a neurological disorder. Cell and gene therapies will play an important role in the treatment of neurological disorders in the future.

The method of delivery of a drug to the CNS has an impact on the drug's commercial potential. The market for CNS drug delivery technologies is directly linked to the CNS drug market. Values are calculated for the total CNS market and the share of drug delivery technologies. Estimates are made for the year 2005 based on current markets and projections are made to the year 2015. The markets values are tabulated according to therapeutic areas, technologies and geographical areas. Unmet needs for further development in CNS drug delivery technologies are identified according to the important methods of delivery of therapeutic substances to the CNS. Finally suggestions are made for strategies to expand CNS delivery markets. Besides development of new products, these include application of innovative methods of delivery to older drugs to improve their action and extend their patent life.

Profiles of over 50 companies involved in drug delivery for CNS disorders are presented along with their technologies, products and collaborations. These include pharmaceutical companies that develop CNS drugs and biotechnology companies that provide technologies for drug delivery. A number of cell and gene therapy companies with products in development for CNS disorders are included.

this entire subject is available for 1800 dollars...and 282 pages?

Company Profiles Overview
Abbott Laboratories
Abbott Vascular Devices Division of Abbott Laboratories
Alkermes, Inc.
Andrx Corporation
Atrix Laboratories, Inc.
Bioject Medical Technologies
Biovail Corporation
Boston Scientific
Cima Labs, Inc.
Cordis Corporation
Durect Corporation
Elan Corporation
Elite Pharmaceuticals, Inc.
Enzon Pharmaceuticals, Inc.
Genzyme General
Guidant Corporation
Guilford Pharmaceuticals, Inc.
Jomed
Macrochem Corporation
Medtronic, Inc.
Nastech Pharmaceutical Company, Inc.
Nektar Therapeutics, Inc.
Orapharma, Inc.
Praecis Pharmaceuticals, Inc.
Skyepharma Plc
Watson Pharmaceuticals, Inc.